.png)
.png)
Staff scientist
HJF, USUHS
Disclosure(s): No financial relationships to disclose
Emilie Goguet, PhD, HJF for USUHS, Bethesda, MD.
I obtained my PhD from the University of Nice Sophia Antipolis, Nice, France in 2014 after working on experimental murine and rat models of bone metastases where I studied the use of Fractalkine (CX3CL1) as an immunotherapeutic agent. I then moved to the US in 2015 to pursue a post-doctorate at NCI, Frederick, MD where I studied the use of TLR agonists as local immunotherapeutic agents in a preclinical murine model of lung metastases.
In 2018, I joined the team of Dr Edward Mitre at USUHS, Bethesda, MD to work on an experimental murine model of allergic asthma to study the underlying mechanisms of the Th2 response involved in that disease. In August of 2020, we launched a clinical study on COVID-19 to study the immunological actors involved in the response after viral infection and after vaccination.